BIORESTORATIVE THERAPIES INC. - COMMON STOCK

BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

13 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

07 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

02 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

08 Feb 2023 09:00:01 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

06 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

29 Nov 2022 11:20:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

16 Nov 2022 08:56:00 By Nasdaq GlobeNewswire

BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show

20 Oct 2022 09:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

28 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

27 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

07 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

30 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

22 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

13 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

29 Apr 2022 08:00:01 By Nasdaq GlobeNewswire